Phoenix, AZ (PRWEB) June 29, 2005
An additional five thousand researchers studying neurological and mental health disorders gained access to 5AM SolutionsÂ Microarray Enterprise Manager (MEM) this month. MEM provides researchers with a tool to speed their access to microarray technology available through the NIH Neuroscience Microarray Consortium, and allows them to collaborate with other NIH-funded researchers and the consortiumÂs Institutes of Excellence. The Phoenix, Arizona-based 5AM Solutions also announced that the firm has opened an office in the Washington, DC area to serve clients and access their network of talent and contacts on the East Coast.
In 2002, the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH) awarded a grant to the consortium to make microarray technology available to neuroscientists whose research was funded by the two institutes. At that time, the consortium, which included the Translational Genomics Research Institute (TGen), UCLA, and Duke University, needed a ÂbridgeÂ between it and scientists seeking to take advantage of sophisticated technology that allows them to compare genes in normal and diseased tissues. 5AM Solutions developed an internet-based tool that manages workflow, collaboration, and communication between the scientists and the consortium.
In June 2005, NINDS, NIMH, and thirteen other institutes that comprise the NIH Neuroscience Blueprint (http://neuroscienceblueprint.nih.gov/) awarded a $25 million grant to the consortium which included funds to bring microarray technology to an additional five thousand grant holders, added Yale University as a Center of Excellence and renamed the consortium to reflect its broader scope. 5AM Solutions Chief Architect Eric Tavela was pleased to learn that the consortium would continue to use MEM and 5AM to support their efforts. "Building a national, completely web-based enterprise solution guided by leaders in the field of neuroscience research and microarray technology was extremely rewarding.Â 5AM CEO Brent Gendleman said, ÂKnowing that we contributed to their management and informatics efforts and that they have been rewarded with additional funding confirms that we are delivering quantifiable return on investment.Â
Dietrich Stephan Ph.D., chairman of the consortium and director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), was enthusiastic about expanding access to the consortiumÂs microarray technology. "The 5AM team has been dedicated to serving the entire consortium from day one, enabling us to collect, monitor and share our results and grant access to the exciting technology and collective expertise to a national audience.Â
5AM SolutionsÂ new Northern Virginia office reflects the firmÂs growth. According to VP Operations Susan Mason, ÂNorthern Virginia is an ideal base for us to better serve our East Coast clients. We are actively seeking teaming opportunities and have established deals with GSA Schedule holders to make it easy for our target clients to access our talent. There are ample opportunities for us to apply our software development expertise to the wide range of established industries Â including the DC-areaÂs biotech market Â and use our software assets such as MEM to support customization services.Â
About 5AM Solutions
5AM builds software solutions for the life sciences. Web-based, interoperable solutions that integrate with third-party systems, support industry guidelines and standards, and grant insight into the complex data produced by the genomic revolution represent a core of 5AMÂs expertise. 5AM shares a common passion to advance medicine and science by contributing state-of-the-art software engineering services. http://www.5amsolutions.com
About the NIH Neuroscience Microarray Consortium
The Consortium is comprised of microarray core facilities at TGen, UCLA, Yale, and Duke University. These institutes collectively provide advanced microarray technology and other resources to researchers who are committed to curing pervasive neurological and mental disorders and diseases and whose work is funded by any of the NIH Neuroscience Blueprint Institutes.
# # #